|
1
|
Asiedu MK, Beauchamp-Perez FD, Ingle JN,
Behrens MD, Radisky DC and Knutson KL: AXL induces
epithelial-to-mesenchymal transition and regulates the function of
breast cancer stem cells. Oncogene. 33:1316–1324. 2014. View Article : Google Scholar
|
|
2
|
Gjerdrum C, Tiron C, Høiby T, Stefansson
I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT,
et al: Axl is an essential epithelial-to-mesenchymal
transition-induced regulator of breast cancer metastasis and
patient survival. Proc Natl Acad Sci USA. 107:1124–1129. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell. 10:515–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meyer AS, Miller MA, Gertler FB and
Lauffenburger DA: The receptor AXL diversifies EGFR signaling and
limits the response to EGFR-targeted inhibitors in triple-negative
breast cancer cells. Sci Signal. 6:ra662013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tonetti DA, Gao W, Escarzaga D, Walters K,
Szafran A and Coon JS: PKCα and ERβ Are Associated with
Triple-Negative Breast Cancers in African American and Caucasian
Patients. Int J Breast Cancer. 2012:7403532012. View Article : Google Scholar
|
|
6
|
Ouelaa-Benslama R, De Wever O, Hendrix A,
Sabbah M, Lambein K, Land D, Prévost G, Bracke M, Hung MC, Larsen
AK, et al: Identification of a GαGβγ, AKT and PKCα signalome
associated with invasive growth in two genetic models of human
breast cancer cell epithelial-to-mesenchymal transition. Int J
oncol. 41:189–200. 2012.PubMed/NCBI
|
|
7
|
Frankel LB, Lykkesfeldt AE, Hansen JB and
Stenvang J: Protein Kinase C alpha is a marker for antiestrogen
resistance and is involved in the growth of tamoxifen resistant
human breast cancer cells. Breast Cancer Res Treat. 104:165–179.
2007. View Article : Google Scholar
|
|
8
|
Tonetti DA, Morrow M, Kidwai N, Gupta A
and Badve S: Elevated protein kinase C alpha expression may be
predictive of tamoxifen treatment failure. Br J Cancer.
88:1400–1402. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Assender JW, Gee JM, Lewis I, Ellis IO,
Robertson JF and Nicholson RI: Protein kinase C isoform expression
as a predictor of disease outcome on endocrine therapy in breast
cancer. J Clin Pathol. 60:1216–1221. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lønne GK, Cornmark L, Zahirovic IO,
Landberg G, Jirström K and Larsson C: PKCalpha expression is a
marker for breast cancer aggressiveness. Mol Cancer. 9:762010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim J, Thorne SH, Sun L, Huang B and
Mochly-Rosen D: Sustained inhibition of PKCα reduces intravasation
and lung seeding during mammary tumor metastasis in an in vivo
mouse model. Oncogene. 30:323–333. 2011. View Article : Google Scholar
|
|
12
|
Li Z, Wang N, Fang J, Huang J, Tian F, Li
C and Xie F: Role of PKC-ERK signaling in tamoxifen-induced
apoptosis and tamoxifen resistance in human breast cancer cells.
Oncol Rep. 27:1879–1886. 2012.PubMed/NCBI
|
|
13
|
Mudduluru G, Leupold JH, Stroebel P and
Allgayer H: PMA up-regulates the transcription of Axl by AP-1
transcription factor binding to TRE sequences via the MAPK cascade
in leukaemia cells. Biol Cell. 103:21–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dufies M, Jacquel A, Belhacene N, Robert
G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S and Auberger P:
Mechanisms of AXL overexpression and function in Imatinib-resistant
chronic myeloid leukemia cells. Oncotarget. 2:874–885. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Keating AK, Kim GK, Jones AE, Donson AM,
Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A
and Graham DK: Inhibition of Mer and Axl receptor tyrosine kinases
in astrocytoma cells leads to increased apoptosis and improved
chemosensitivity. Mol Cancer Ther. 9:1298–1307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsieh YH, Wu TT, Tsai JH, Huang CY, Hsieh
YS and Liu JY: PKCalpha expression regulated by Elk-1 and MZF-1 in
human HCC cells. Biochem Biophys Res Commun. 339:217–225. 2006.
View Article : Google Scholar
|
|
17
|
Song X and Wang H, Logsdon CD, Rashid A,
Fleming JB, Abbruzzese JL, Gomez HF, Evans DB and Wang H:
Overexpression of receptor tyrosine kinase Axl promotes tumor cell
invasion and survival in pancreatic ductal adenocarcinoma. Cancer.
117:734–743. 2011. View Article : Google Scholar
|
|
18
|
Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E,
Reinhardt F, Wu ZJ, Krall JA, Bierie B, Guo W, et al: Protein
kinase C α is a central signaling node and therapeutic target for
breast cancer stem cells. Cancer Cell. 24:347–364. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mudduluru G, Vajkoczy P and Allgayer H:
Myeloid zinc finger 1 induces migration, invasion and in vivo
metastasis through Axl gene expression in solid cancer. Mol Cancer
Res. 8:159–169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH,
Ambs S and Caplen NJ: Identification of the receptor tyrosine
kinase AXL in breast cancer as a target for the human miR-34a
microRNA. Breast Cancer Res Treat. 130:663–679. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vuoriluoto K, Haugen H, Kiviluoto S,
Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J:
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and
migration by governing Axl expression in breast cancer. Oncogene.
30:1436–1448. 2011. View Article : Google Scholar
|
|
22
|
Kyuno D, Kojima T, Yamaguchi H, Ito T,
Kimura Y, Imamura M, Takasawa A, Murata M, Tanaka S, Hirata K and
Sawada N: Protein kinase Cα inhibitor protects against
downregulation of claudin-1 during epithelial-mesenchymal
transition of pancreatic cancer. Carcinogenesis. 34:1232–1243.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paccez JD, Vogelsang M, Parker MI and
Zerbini LF: The receptor tyrosine kinase Axl in cancer: Biological
functions and therapeutic implications. Int J Cancer.
134:1024–1033. 2014. View Article : Google Scholar
|
